

## DAFTAR PUSTAKA

1. Douglas B. Duchenne muscular dystrophy. *Pediatr.Rev.* 2006;27:83-8
2. Strober JB. Therapeutics in duchenne muscular dystrophy. *NeurTx.* 2006;3:225-34
3. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Constantin C, et al. Diagnosis and management of duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.* 2009;9:77-93
4. Emery A. Duchenne muscular dystrophy. Oxford: Oxford university press, 1993
5. Manzur AY, Kuntzer T, Pike M and Swan AV. Glucocorticoid corticosteroids for duchenne muscular dystrophy. *Cochrane Database of Systematic Reviews.* 2008
6. Brooke M, Fenichel GM, Griggs RC, Mendell JR, Moxley R. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. *Neurology.* 1989;39:475-81
7. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. *Neuromusc Disord.* 2002;12:926–29
8. Essen A, Verheij J, Reefhuis J, Fidler V, Beeger JH, Kate LP, et al. The natural history of duchenne muscular dystrophy; analysis of data from a dutch survey and review of age related events. [www.DMD.nl](http://www.DMD.nl). 1999
9. Muntoni F, Torelli S, and Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol.* 2003;2:731–40
10. Sussman M. Duchenne muscular dystrophy. *J Am Acad Orthop Surg.* 2002;10:138–51
11. Alman BA, Raza SN, and Biggar WD. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy. *J Bone Joint Surg Am.* 2004; 86:519–24
12. David J. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. *Pediatric Pulmonol.* 2010;5:67-9
13. Moxley RT, Ashwal S, and Pandya S. Practice parameter:corticosteroid treatment of duchenne dystrophy: report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society. *Neurology.* 2005; 64(1):13–20



14. Sultan A and Fayaz M. Prevalence of cardiomyopathy in duchenne muscular dystrophy. *J Ayub Med Coll Abbottabad*. 2008;20(2):56-69
15. American academy of pediatrics section on cardiology and cardiac surgery. cardiovascular health supervision for individuals affected by duchenne or becker muscular dystrophy. *Pediatrics*. 2005;116:1569–73.
16. Chenard AA, Becane HM, Tertrain F, Kermadec JM, and Weiss YA. Ventricular arrhythmia in duchenne muscular dystrophy: prevalence, significance and prognosis. *Neuromuscul Disord*. 1993;3:201–06.
17. Gulati S, Saxena A, Kumar V, and Kalra V. Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. *Indian J Pediatr*. 2005;72:386-93
18. Guzman OR, Garsia A, and Cruz MR. Muscular dystrophies at different age: metabolic and endocrine alterations. *Int J Endocrin*, 2012;30:31-6
19. Leung DG, Lee EL, Denger BE, and Wagner KR. Report on the second endocrine aspects of duchenne muscular dystrophy conference. *Neuromuscul Disord*. 2011;30:130-41
20. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Constantin C, et al. Diagnosis and management of duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol*. 2009;9:177-89
21. Marsh G and Munsat TL. Evidence of early impairment of verbal intelligence in duchenne muscular dystrophy. *Arch Dis Child*. 1974;49:118-22.
22. Smith R, Sibert J, Wallace S, and Harper P. Early diagnosis and secondary prevention of duchenne muscular dystrophy. *Arch Dis Child*. 1989;64:787-90
23. Jackson C, Clinical approach to muscle disease. *Semin neurol*. 2008;28(2):228-40
24. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL index: a reliability study, *Int. Disabil. Stud*. 1988;10(2),61-63
25. Bianchi ML. Osteoporosis in children and adolescents. *Bone*. 2007;41:486-95
26. Griffiths R and Edwards R. A new chart for weight control in duchenne muscular dystrophy. *Arch Dis Child*. 1988;63:1256-58
27. Goodman, R.. Psychometric properties of the Strengths and Difficulties Questionnaire (SDQ). *J Am Acad Child Adolesc Psychiatry*. 2001;40:1337-45
28. Varni JW and Limbers CA. The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents: *Pediatr. Clin. North Am* .2009;56:843-63.



29. Varni JW, Seid M., Knight TS, Uzark K, and Szer IS, The PedsQL 4.0 generic core scales: sensitivity, responsiveness, and impact on clinical decision-making: *J.Behav.Med.* 2002; 25: 175-93.
30. Biggar, WD. Duchenne muscular dystrophy. *Pediatrics in Review*, 2006;27(3):83–8
31. Tangsrud SE and Petersen IL, Carlsen KCL and Carlsen KH. Lung function in children with duchenne’s muscular dystrophy. *Respiratory Medicine*. 2001;95:898-903
32. Angelini C and Peterle E, , Old and new therapeutic developments in steroid treatment in duchenne muscular dystrophy, *Acta Myologica*. 2012;31:15
33. Mehta JS and Gibson MJ. The treatment of neuromuscular scoliosis. *Current Orthopaedics*. 2003;17:313-21.
34. Muntoni A, Bushby K, and Manzur YA. Muscular dystrophy campaign funded workshop on management of scoliosis in duchenne muscular dystrophy. *Neuromuscul Disord*. 2006;16:210–19
35. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksman G, and Be’cane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in duchenne muscular dystrophy. *J Am Coll Cardiol*. 2005;45(6):855–57
36. Ogata H, Ishikawa Y, and Ryoji MR. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy *Journal of Cardiology* , 2009;53:72-78
37. Fayssol A, Nardi O, Orlikowski D, and Annane D. Cardiomyopathy in duchenne muscular dystrophy: pathogenesis and therapeutics. *Heart Fail Rev*. 2010;15:103–07
38. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, and Cripe LH. Steroid therapy and cardiac function in Duchenne muscular dystrophy. *Pediatr Cardiol*. 2005; 26:768–71
39. Gordon KE, Dooley JM, Sheppard KM, Macsween J, and Esser MJ, Impacts of biphosphonates on survival for patients with duchenne muscular dystrophy. *Pediatrics*. 2011;127:353–58
40. Poysky J, Behavior in DMD Study Group. Behavior patterns in duchenne muscular dystrophy: report on the parent project muscular dystrophy behavior workshop 8–9 of December 2006, Philadelphia, USA. *Neuromuscul Disord* 2007;17:986–94
41. Bushby K, Bourke J, Bullock R, Eagle M, Gibson M and Quinby J. The multidisciplinary management of duchenne muscular dystrophy. *Current Paediatrics*. 2005;15:292-300